| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_204587e95ece0e90f9fb0e087631b5bb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate |
2008-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad66e194e9396af5546df81f9427bd5d |
| publicationDate |
2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008262006-A1 |
| titleOfInvention |
Selective endothelin type-a antagonists |
| abstract |
This invention relates to novel endothelin receptor antagonists that selectively inhibit the interaction between Endothelin-1 (ET-1) and endothelin type-A receptors, their derivatives, acceptable acid addition salts. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by endothelin receptor antagonists, particularly those diseases and conditions that are beneficially treated by selective inhibitors of endothelin type-A receptors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008255036-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8404840-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103755569-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011263854-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7863308-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009069353-A1 |
| priorityDate |
2007-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |